Volume 33, No 3, Mar 2023

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 33 Issue 3, March 2023: 197-198

RESEARCH HIGHLIGHTS

Immune checkpoint inhibitors as senolytic agents

Parminder Singh¹ , Pankaj Kapahi¹ , Jan M. van Deursen^2,*

¹Buck Institute for Research on Aging, Novato, CA, USA
²Cavalry Biosciences, Novato and San Francisco, CA, USA
Correspondence: Jan M. van Deursen(janvandeursen2@gmail.com)

Senolysis, the elimination of senescent cells (SNCs), is a novel therapeutic concept for the treatment of aging and age-related diseases that has scored a first success in the clinic for the treatment of diabetic macular edema with UBX1325. In a recent Nature paper, Wang et al. now report that subsets of SNCs express PD-L1 and describe a novel mode of senolysis through clearance of these cells by immune checkpoint inhibitors.

https://doi.org/10.1038/s41422-022-00761-4

FULL TEXT | PDF

Browse 378